Clinical Trials Logo

Angiosarcoma clinical trials

View clinical trials related to Angiosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04518124 Completed - Angiosarcoma Clinical Trials

Propranolol in Angiosarcoma

Start date: December 27, 2019
Phase: Phase 2
Study type: Interventional

This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of this study is to prospectively evaluate the activity of propranolol in the clinical setting as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate both the clinical response and histological response, without a significant delay in anti-cancer treatment.

NCT ID: NCT04293289 Completed - Malignant Melanoma Clinical Trials

Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma

Start date: November 19, 2019
Phase: N/A
Study type: Interventional

Among skin malignancies, patients with malignant melanoma or angiosarcoma are treated with BNCT using CICS-1 and SPM-011 (borofalan (10B)). Through this trial, safety and appropriate treatment dose will be determined.

NCT ID: NCT02584309 Completed - Soft Tissue Sarcoma Clinical Trials

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Start date: February 22, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to look at whether giving a drug called dexrazoxane with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is often given at the same time as doxorubicin to help reduce the incidence and severity of disease of the heart muscle (which can be caused by doxorubicin). In January 2019 Eli Lilly and Company reported that the results of the Phase 3 study of olaratumab (Lartruvo), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma, did not confirm the clinical benefit of olaratumab in combination with doxorubicin as compared to doxorubicin alone. Therefore olaratumab is being removed from the front line standard of care regimen. Amendment #9 was made to the protocol to reflect these changes to the standard of care treatment.

NCT ID: NCT01303497 Completed - Angiosarcoma Clinical Trials

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

ANGIO-TAX+
Start date: September 10, 2010
Phase: Phase 2
Study type: Interventional

Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma

NCT ID: NCT00887809 Completed - Sarcoma Clinical Trials

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.